Application of an Improved Method for the Recombinant K 39 Enzyme-linked Immunosorbent Assay to Detect Visceral Leishmaniasis Disease and Infection in Bangladesh
Overview
Authors
Affiliations
Several serology-based immunoassays are used to diagnose visceral leishmaniasis (VL), a chronic protozoan parasitic disease caused by the Leishmania donovani complex. These tests are primarily designed to diagnose the most severe clinical form of VL, known as kala-azar. However, leishmanial infection is frequently asymptomatic and may manifest only as a positive serologic response or positive leishmanin skin test. We modified a previously described enzyme-linked immunosorbent assay (ELISA) that detects patient antibodies reactive with the recombinant Leishmania protein K39 (rK39) to confirm suspected kala-azar and to detect asymptomatic infection in a community study in Bangladesh. With the inclusion of a standard curve on each ELISA plate, the rK39 ELISA was more repeatable (kappa coefficient of agreement=0.970) and more reliable compared to the original method (kappa=0.587, P<0.001). The cutoff point for a positive antibody response was chosen based on the 99th percentile of the ELISA distribution for the negative-control sera. However, we found that sera from all patients with active kala-azar yielded values more than twice the magnitude of this cutoff. Using receiver-operator characteristic curves, we determined a second cutoff value predictive of kala-azar. Using these criteria, the sensitivity and specificity of the modified ELISA for kala-azar were 97.0% and 98.9%, respectively, for sera from our study population. We hypothesize that individuals with antibody levels greater than the 99th percentile of the negative controls but less than the cutoff point for kala-azar have asymptomatic leishmanial infections.
Chan Y, Martin D, Mace K, Jean S, Stresman G, Drakeley C Front Public Health. 2022; 10:897013.
PMID: 35757611 PMC: 9218545. DOI: 10.3389/fpubh.2022.897013.
Rodrigues W, Mendes N, de Carvalho Ribeiro P, Filho D, Parreira R, Chaves K J Parasit Dis. 2021; 45(1):109-117.
PMID: 33746394 PMC: 7921252. DOI: 10.1007/s12639-020-01283-9.
Fujimori M, de Almeida A, Barrouin-Melo S, de Barros Cortez L, Duthie M, Hiramoto R Mem Inst Oswaldo Cruz. 2021; 116:e200428.
PMID: 33729396 PMC: 7968437. DOI: 10.1590/0074-02760200428.
Deepachandi B, Weerasinghe S, Ranasinghe S, Andrahennadi T, Wickramanayake M, Siri S Biomed Res Int. 2020; 2020:5271657.
PMID: 33145352 PMC: 7599090. DOI: 10.1155/2020/5271657.
Prevalidation of an ELISA for Detection of a New Clinical Entity: -Induced Cutaneous Leishmaniasis.
Deepachandi B, Weerasinghe S, Gunathilake H, Andrahennadi T, Wickramanayake M, Siri S Int J Anal Chem. 2020; 2020:9289651.
PMID: 32733568 PMC: 7378632. DOI: 10.1155/2020/9289651.